Coherus Oncology, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Redwood City, CA. Its latest filed balance sheet (2025-12-31) shows total assets of $266 million (its filed statements).
Pre-revenue companyBiological Products, (No Diagnostic Substances)Redwood City, CAfilings since 20118 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 4.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.1 out of ten, present 5.7 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 0.1 out of ten. 3 warning events since 2017; the latest 2026-06-15. 1st percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 3.3 out of ten. -15.4% a year over 10 filed years; profitable in 4 of 10. 33rd percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 35 of 100 (one part). 49th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 6.3 out of ten. ROE 275%: 275¢ of profit per shareholder dollar. Leverage 76%: owes 76¢ per asset dollar. 63rd percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 5.6 out of ten. top 44% of 102 in its family; net margin 398.4%. 56th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 4.8 out of ten. bottom 48% of 108 in its family for leadership; chief executive since 2014. 48th percentile among 108 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 5.1 out of ten. top 49% of 92 in its family for room to expand. 51st percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 3.1 out of ten. bottom 31% of 100 in its family for growth drivers. 31st percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.6 out of ten. top 14% of 72 in its family for expectations against reality. 86th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-09 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 8-K, 2026-08-28. Filings on record since 2011. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Toripalimab 97%, Product and Service Other 3%. As tagged in its annual report (Form 10-K, filed 2026-03-09).
Who runs it
Lanfear, Dennis M (President & CEO); Mcmichael, Bryan J (Chief Financial Officer); Karachun, Rita A (director); Newcomer, Lee Nisley (director); Newton, Charles W. (director); O'Donnell-Tormey, Jill (director); Ryan, Michael Lee (director); Satvat, Ali J. (director); Wahlstrom, Mats (director). 9 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.